CAR-T - In Cancer: A "Living Drug" New Era of Cancer Therapy

The CAR-T cell therapy is a ground-breaking new component in the treatment of cancer. The therapeutic efficiency of CAR-T cells in solid tumours and haematological malignancies is constrained by a number of obstacles, despite the fact that treatment with CAR-T cells has shown significant clinical responses with some subsets of B cell leukemia or lymphoma. Severe toxicities that can be fatal, poor anti-tumor effectiveness, antigen evasion, restricted trafficking, and minimal tumor penetration are all obstacles to effective CAR-T cell therapy. Additionally, CAR-T cell activity is significantly changed by interactions between the host and tumor microenvironment. These treatments must also be developed and implemented by a sophisticated staff. Innovative tactics and methods to create more potent CAR-T cells with greater anti-tumor activity and less toxicity are required to address these important difficulties. The CRISPR approach is expected to make genetically edited T cell immunotherapies safe, well tolerated, and effective medicines that will give cancer patients hope. In this review, we cover recent developments in CAR-T cell engineering to enhance clinical effectiveness in solid tumors and haematological malignancies, as well as the benefits and drawbacks of CAR-T cell treatment using CRISPR.